A5035708719- Advanced Breast Cancer Therapies
- Cancer Treatment and Pharmacology
- Breast Cancer Treatment Studies
- PARP inhibition in cancer therapy
- Cancer survivorship and care
- Microtubule and mitosis dynamics
- Economic and Financial Impacts of Cancer
- Complementary and Alternative Medicine Studies
- Cancer, Lipids, and Metabolism
- BRCA gene mutations in cancer
- Glioma Diagnosis and Treatment
- Chemotherapy-induced cardiotoxicity and mitigation
- Lung Cancer Research Studies
- Cancer Genomics and Diagnostics
- Palliative Care and End-of-Life Issues
- Global Cancer Incidence and Screening
- Acupuncture Treatment Research Studies
- Tryptophan and brain disorders
- Cardiovascular and exercise physiology
- Pain Management and Placebo Effect
- Neuroblastoma Research and Treatments
- HER2/EGFR in Cancer Research
- Brain Metastases and Treatment
- Cancer-related cognitive impairment studies
- Telomeres, Telomerase, and Senescence
University of Illinois Chicago
2016-2025
University of Illinois Urbana-Champaign
2021-2024
Illinois College
2020-2024
The Ohio State University
2023
Hershey (United States)
2019
Rutgers, The State University of New Jersey
2019
Michigan State University
2019
University of Michigan
2019
University of Wisconsin–Madison
2019
University of California, Los Angeles
2019
In this study, the mechanisms of actin-bundling in filopodia were examined. Analysis cellular localization known actin cross-linking proteins mouse melanoma B16F1 cells revealed that fascin was specifically localized along entire length all filopodia, whereas other cross-linkers not. RNA interference reduced number and remaining had abnormal morphology with wavy loosely bundled organization. Dephosphorylation serine 39 likely determined frequency. The constitutively active mutant S39A...
Given the widespread use of 21-gene recurrence score for identifying candidates adjuvant chemotherapy, it is important to examine performance Oncotype DX Breast Recurrence Score test in diverse patient populations validate this approach tailoring treatment women racial/ethnic minority groups.To whether breast cancer-specific mortality with hormone-dependent cancer differs by race/ethnicity across risk categories defined and prognostic accuracy race/ethnicity.This retrospective,...
Black women with hormone receptor-positive breast cancer experience the greatest racial disparity in survival of all subtypes. The relative contributions social determinants health and tumor biology to this are uncertain.
Abstract African American (AA) women in the United States have a 40% higher breast cancer mortality rate than Non-Hispanic White (NHW) women. The survival disparity is particularly striking among (estrogen receptor positive) ER + cases. purpose of this study to examine whether there are racial differences metabolic pathways typically activated patients with cancer. We collected pretreatment plasma from AA and NHW ER+ cases (AA n = 48, 54) cancer-free controls 100, 48) conduct an untargeted...
Background/Objectives: Breast cancer survivors undergoing long-term endocrine therapy often experience multiple symptoms, including pain, fatigue, sleep disturbance, hot flashes, anxiety, and depression. This study explored the feasibility acceptability of integrating acupuncture for symptom management in medically underserved breast survivors. Methods: randomized controlled trial was conducted at two clinics serving populations. (N = 62) were to receive (n 31) or usual care 31). The group...
Indoleamine 2,3-dioxygenase 1 (IDO1) causes tumor immune suppression. The IDO1 pathway inhibitor indoximod combined with a taxane in patients ERBB2-negative metastatic breast cancer was tested prospective clinical trial.To assess outcomes treated plus taxane.This phase 2 double-blinded randomized 1:1 placebo-controlled trial enrolled at multiple international centers from August 26, 2013, to January 25, 2016. Eligibility criteria included cancer, ability receive therapy, good performance...
Mixed lineage kinase 3 (MLK3), also known as MAP3K11, was initially identified in a megakaryocytic cell line and is an emerging therapeutic target cancer, yet its role immune cells not known. Here, we report that loss or pharmacological inhibition of MLK3 promotes activation cytotoxicity T cells. abundantly expressed cells, alters serum chemokines, cytokines, CD28 protein expression on subsets. induces vitro, ex vivo, vivo conditions, irrespective activating agents. Conversely,...
Cytoplasmic linker protein (CLIP)-170 is a microtubule (MT) plus-end-tracking that regulates MT dynamics and links plus ends to different intracellular structures. We have shown previously intramolecular association between the N C termini results in autoinhibition of CLIP-170, thus altering its binding MTs dynactin subunit p150(Glued) (J. Cell Biol. 2004: 166, 1003-1014). In this study, we demonstrate conformational changes CLIP-170 are regulated by phosphorylation enhances affinity N-...
Telomerase catalyzes telomeric DNA synthesis at chromosome ends to allow for continued cell division. The protein TPP1 is essential enhancing the processivity of telomerase and recruiting enzyme telomeres. interaction surface on human has been mapped 2 regions N-terminal oligosaccharide/oligonucleotide-binding (OB) domain, namely glutamate (E) leucine (L)-rich (TEL) patch N terminus TPP1-oligosaccharide/oligonucleotide-binding (NOB) region. To map side interface, we exploited predicted...
Pazopanib is a multikinase angiogenesis inhibitor. Alisertib highly selective inhibitor of mitotic Aurora A kinase. There preclinical evidence that mitosis-targeting agents exhibit antiangiogenic effects. Thus, the combination these 2 may have synergistic effect on tumor vasculature. The primary objective this study to determine optimal tolerated dose (OTD) for alisertib and pazopanib.This phase 1b evaluated OTD twice day, days 1 7 with pazopanib, once continuously in 21-day cycle, both...
Trastuzumab is the first-line therapy for human epidermal growth factor receptor 2-positive (HER2 + ) breast cancer, but often patients develop acquired resistance. Although other agents are in clinical use to treat trastuzumab-resistant (TR) cancer; still, recurrent metastatic disease. One of primary mechanisms resistance shedding/loss HER2 extracellular domain, where trastuzumab binds. We envisioned any new agent acting downstream should overcome The mixed lineage kinase 3 (MLK3)...
e12658 Background: Triple-negative breast cancer (TNBC) has limited treatment options. KEYNOTE 522 led to the approval of neoadjuvant (NT) Pembrolizumab in July 2021 changing paradigm for early stage TNBC. While improving pathologic complete response it also slightly increased related adverse events. Some studies show risk venous thromboembolism (VTE) with Pembrolizumab; however, is unclear if immunotherapy (IO) increases VTE a NT setting. Breast not classically associated high VTE. Here, we...
Abstract Background: To date, the use of anti-androgens in subset triple negative breast cancers (TNBC) that express androgen receptor (AR) has shown modest response rates, indicating anti-androgen-resistance majority these tumors. Based on data Cyclin D kinase (CDK) inhibitors reverse resistance to prostate cancer cell lines, we hypothesize CDK inhibition may enhance activity AR-positive TNBC. Methods: Key eligibility include: patients with centrally confirmed TNBC, defined as AR expression...
Abstract Background Procaspase-3 (PC-3) is overexpressed in various tumor types, including gliomas. Targeted PC-3 activation combined with chemotherapy a novel strategy for treating patients high-grade gliomas, promising preclinical activity. This study aimed to define safety and tolerability of procaspase-activating compound-1 (PAC-1) combination temozolomide (TMZ) recurrent astrocytomas. Methods A modified-Fibonacci dose-escalation 3 + design was used. PAC-1 administered at increasing dose...
Objectives: Insulin-like growth factor-methotrexate (IGF-MTX) is a conjugate of methotrexate and 765IGF, variant IGF-1 with high affinity for insulin-like factor type 1 receptor. The study aim was to determine the maximum tolerated dose IGF-MTX in refractory solid organ hematologic malignancies expressing Materials Methods: This phase I trial used modified toxicity probability interval design 5 cohort levels, expansion at dose. given intravenously over 90 minutes on days 1, 8, 15 28-day...
Objective Approximately 24–68% of breast cancer survivors report co-occurring psychoneurological symptoms pain, fatigue, sleep disturbance, depression, and anxiety during after treatment. This study aimed to assess the feasibility acceptability acupuncture for treatment multiple among explore metabolomic changes before acupuncture. Methods We conducted a single-arm, prospective pilot with at least two moderate severe (>3 on 0–10 scale). Acupuncture was administered twice weekly 5 weeks,...
TPS2605 Background: Members of the caspase family cysteine proteases are key players in both initiation and execution apoptosis; activation procaspase-3 to caspase-3 is a critical event apoptotic cascade. Procaspase-3 levels elevated in: glioblastoma, breast cancer, colon lung lymphoma, neuroblastoma, melanoma, liver cancer. As consequence, abnormally low these tumors, allowing tumors avoid apoptosis. PAC-1 small molecule that directly activates induces apoptosis cancer cells culture. showed...
1009 Background: African American breast cancer patients (AA) are diagnosed younger, have more high-risk features, and poorer clinical outcomes than non-Hispanic White (NHW), despite similar treatments. Although comorbidities such as obesity metabolic syndrome may contribute to differences, ancestry-specific factors effects of structural violence that disproportionately afflict AA individuals influence tumor biology outcomes. We previously reported differentially expressed genes (DEGs)...
Background: We previously showed the 21-gene breast recurrence score (RS) has lower prognostic accuracy for non-Hispanic Black (NHB) compared with White (NHW) women estrogen receptor (ER)–positive/HER2-negative cancer. The purpose of this study was to determine clinical validity RS predicting chemotherapy benefit as recommended in current NCCN Guidelines Breast Cancer among from diverse racial/ethnic groups. Methods: Using SEER Oncotype database, we estimated propensity score–weighted hazard...